NCT02038010View on ClinicalTrials.gov

BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

May 21, 2014

Primary Completion Date

April 15, 2015

Study Completion Date

May 20, 2017

Conditions
HER2-positive Breast CancerRecurrent Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast Cancer
Interventions
DRUG

PI3K inhibitor BYL719

Given PO

BIOLOGICAL

ado-trastuzumab emtansine

Given IV

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Optional correlative studies

Trial Locations (1)

60611

Northwestern University, Chicago

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER